Sakar Healthcare

Which are the latest news on Sakar Healthcare?

Why is Sakar Healthcare Ltd falling/rising?

As of 05-Sep, Sakar Healthcare Ltd's stock price is rising due to significant financial growth, with a net profit increase of 120.13% and strong performance compared to the benchmark Sensex. The stock is trading above its moving averages and is close to its 52-week high, supported by high institutional holdings.

As of 05-Sep, Sakar Healthcare Ltd's stock price is rising, currently at 1,013.90, reflecting an increase of 6.95 (0.69%). This upward movement can be attributed to several positive factors. The company has reported significant growth in its financial performance, with a net profit increase of 120.13% and consistent positive results over the last seven consecutive quarters. Additionally, the stock has outperformed the benchmark Sensex, showing a remarkable 197.37% return over the past year, while the Sensex has declined by 3.38% during the same period.<BR><BR>Moreover, Sakar Healthcare is trading above its moving averages across various time frames, indicating strong momentum. The stock is also close to its 52-week high, just 1% away from Rs 1,024, which suggests continued investor interest. High institutional holdings at 23.51% further bolster confidence, as these investors typically have more resources to analyze the company's fundamentals.<BR><BR>Despite a recent decline in delivery volume, which fell by 28.25% against the 5-day average, the overall market performance and the company's strong financial results contribute to the stock's rising price. Thus, the combination of robust financial growth, market outperformance, and institutional backing are key reasons for the rise in Sakar Healthcare Ltd's stock price.

Should I buy, sell or hold Sakar Healthcare Ltd?

Who are in the management team of Sakar Healthcare?

The management team of Sakar Healthcare includes Sanjay S Shah (Chairman & Managing Director), Aarsh S Shah (Joint Managing Director), Ritaben S Shah (Whole-time Director), and independent directors Shailesh B Patel, Prashant C Srivastav, and Hemendrakumar C Shah. They are responsible for the company's strategic direction and operations.

The management team of Sakar Healthcare includes the following individuals:<BR><BR>1. **Sanjay S Shah** - Chairman & Managing Director<BR>2. **Aarsh S Shah** - Joint Managing Director<BR>3. **Ritaben S Shah** - Whole-time Director<BR>4. **Shailesh B Patel** - Independent Non-Executive Director<BR>5. **Prashant C Srivastav** - Independent Non-Executive Director<BR>6. **Hemendrakumar C Shah** - Independent Non-Executive Director<BR><BR>This team plays a crucial role in guiding the company's strategic direction and operations.

What does Sakar Healthcare do?

Sakar Healthcare Ltd is a Micro Cap company in the Pharmaceuticals & Biotechnology industry, incorporated in 2004 and publicly listed since 2015. As of June 2026, it reported net sales of 73 Cr and a net profit of 10 Cr, with a market cap of INR 1,920 Cr.

Overview: <BR>Sakar Healthcare Ltd operates in the Pharmaceuticals & Biotechnology industry and is categorized as a Micro Cap company.<BR><BR>History: <BR>Sakar Healthcare Limited was incorporated as a Private Limited Company on 26th March 2004 and later converted into a Public Limited Company on March 27, 2015. The latest quarterly results report net sales and profit for June 2026.<BR><BR>Financial Snapshot: <BR>Net Sales: 73 Cr (Quarterly Results - Jun 2026) <BR>Net Profit: 10 Cr (Quarterly Results - Jun 2026) <BR>Market Cap: INR 1,920 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 53.00 <BR>Industry P/E: 37 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.17 <BR>Return on Equity: 9.39% <BR>Price to Book: 6.01<BR><BR>Contact Details: <BR>Address: 10/13 Nr MN Desai Petrol Pump, Sarkhej Bavla Highway Changodar Gujarat : 382213 <BR>Tel: 91-2717-250477 <BR>Email: info@sakarhealthcare.com <BR>Website: http://www.sakarhealthcare.com

Who are the peers of the Sakar Healthcare?

Sakar Healthcare's peers include Panacea Biotec, Indoco Remedies, Venus Remedies, Windlas Biotech, Hester Bios, Syncom Formul., NGL Fine Chem, Jagsonpal Pharma, and Shukra Pharma. Sakar Healthcare has average management risk and growth, with a 1-year return of 162.14%, outperforming Panacea Biotec but underperforming Venus Remedies.

Peers: The peers of Sakar Healthcare are Panacea Biotec, Indoco Remedies, Venus Remedies, Windlas Biotech, Hester Bios, Syncom Formul., NGL Fine Chem, Jagsonpal Pharma, and Shukra Pharma.<BR><BR>Quality Snapshot: Excellent management risk is observed at Venus Remedies, Windlas Biotech, Syncom Formul., NGL Fine Chem, Jagsonpal Pharma, and Shukra Pharma, while Average management risk is found at Indoco Remedies, Hester Bios, Sakar Healthcare, and the rest. Growth is rated as Good for Venus Remedies and Excellent for Shukra Pharma, while Average growth is seen at Sakar Healthcare and the rest, with Below Average growth at Panacea Biotec, Indoco Remedies, Windlas Biotech, Hester Bios, and the rest. Capital Structure is Excellent for Venus Remedies, Windlas Biotech, Syncom Formul., NGL Fine Chem, Jagsonpal Pharma, and Shukra Pharma, while Average capital structure is noted for Sakar Healthcare and the rest, with Below Average at Panacea Biotec, Indoco Remedies, Hester Bios.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Venus Remedies at 264.86%, while the lowest is Panacea Biotec at -9.30%. Sakar Healthcare's 1-year return of 162.14% is significantly higher than Panacea Biotec's but lower than Venus Remedies'. Additionally, NGL Fine Chem is the only peer with a negative six-month return at 10.29%.

How big is Sakar Healthcare?

As of 31st August, Sakar Healthcare Ltd has a market capitalization of 1,920.00 Cr, with net sales of 271.97 Cr and a net profit of 36.09 Cr reported in the latest four quarters. The company has shareholder's funds of 324.45 Cr and total assets of 481.01 Cr for the annual period ending March 2026.

As of 31st August, Sakar Healthcare Ltd has a market capitalization of 1,920.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Sakar Healthcare reported net sales of 271.97 Cr and a net profit of 36.09 Cr.<BR><BR>For the latest annual period ending in March 2026, the company had shareholder's funds amounting to 324.45 Cr and total assets of 481.01 Cr.

Are Sakar Healthcare Ltd latest results good or bad?

Sakar Healthcare Ltd's latest results show strong revenue growth of 38.36% and a net profit increase of 120.13% year-on-year; however, profitability concerns arise from a 6.72% decline in net profit compared to the previous quarter and significant drops in operating and PAT margins. Investors should watch for how the company manages these margin pressures.

Sakar Healthcare Ltd's latest results present a mixed picture. On one hand, the company reported a significant year-on-year net profit growth of 120.13%, reaching ₹10.28 crore, and a robust revenue increase of 38.36%, with sales hitting an all-time quarterly high of ₹72.97 crore. This marks the seventh consecutive quarter of revenue growth, which is impressive and indicates strong market performance.<BR><BR>However, there are notable concerns regarding profitability. The net profit decreased by 6.72% compared to the previous quarter, and both the operating margin and PAT margin saw significant declines. The operating margin fell to 29.11% from 36.91% in the previous quarter, reflecting a 773 basis point contraction, while the PAT margin decreased to 14.09% from 15.50%. This margin erosion suggests rising operational challenges that could affect future profitability.<BR><BR>Overall, while the top-line growth is commendable, the decline in margins raises questions about the sustainability of this growth. Investors may need to monitor how the company addresses these margin pressures moving forward.

Is Sakar Healthcare overvalued or undervalued?

As of November 27, 2025, Sakar Healthcare is considered very expensive and overvalued, with a PE Ratio of 42.16 and other key ratios significantly higher than industry norms, indicating it may not be a favorable investment despite strong recent performance.

As of 27 November 2025, Sakar Healthcare's valuation grade has moved from expensive to very expensive. This indicates that the company is currently overvalued. Key ratios supporting this assessment include a PE Ratio of 42.16, an EV to EBIT of 30.26, and a Price to Book Value of 2.72, all of which are significantly higher than industry norms.<BR><BR>In comparison to its peers, Sakar Healthcare's PE Ratio is notably higher than Sun Pharma's 37.62 and Cipla's 22.67, which are categorized as expensive and attractive, respectively. Additionally, the company's EV to EBITDA of 17.37 is also elevated compared to the industry average. Despite a strong performance relative to the Sensex over the past year, with a return of 27.04% versus the Sensex's 7.99%, the current valuation suggests that Sakar Healthcare may not offer a favorable investment opportunity at this time.

Is Sakar Healthcare technically bullish or bearish?

As of November 27, 2025, the technical trend is bullish with strong indicators like MACD and moving averages supporting this view, despite some mildly bearish signals from Dow Theory and OBV on the weekly chart.

As of 27 November 2025, the technical trend has changed from mildly bullish to bullish. The current stance is bullish with strong indicators supporting this view. The MACD is bullish on both the weekly and monthly time frames, and the moving averages on the daily chart confirm a bullish trend. The Bollinger Bands indicate a bullish condition on the monthly and mildly bullish on the weekly. The KST is also bullish on both time frames. However, the Dow Theory shows a mildly bearish signal on the weekly but is mildly bullish on the monthly, and the OBV reflects a similar mildly bearish stance on the weekly while being mildly bullish on the monthly. Overall, the strength of the bullish trend is reinforced by the positive performance against the Sensex over multiple time frames, particularly the 1Y and 5Y returns.

How has been the historical performance of Sakar Healthcare?

Sakar Healthcare has shown consistent growth over the past five years, with net sales increasing from 94.74 Cr in Mar'21 to 177.58 Cr in Mar'25, and profit after tax rising from 10.68 Cr to 17.50 Cr. The company's total assets also expanded significantly, from 115.04 Cr in Mar'20 to 415.26 Cr in Mar'25, indicating strong financial performance.

Answer:<BR>The historical performance of Sakar Healthcare shows a consistent growth trajectory in net sales and profitability over the past five years.<BR><BR>Breakdown:<BR>Sakar Healthcare's net sales have increased from 94.74 Cr in Mar'21 to 177.58 Cr in Mar'25, demonstrating a strong upward trend. Total operating income has followed a similar pattern, rising from 94.74 Cr in Mar'21 to 177.58 Cr in Mar'25. The company's total expenditure has also grown, reaching 127.90 Cr in Mar'25, up from 72.14 Cr in Mar'21, primarily driven by rising raw material costs and employee expenses. Operating profit (PBDIT) has improved significantly, from 22.60 Cr in Mar'21 to 49.68 Cr in Mar'25, indicating enhanced operational efficiency. Profit before tax has increased from 13.23 Cr in Mar'21 to 21.53 Cr in Mar'25, while profit after tax has risen from 10.68 Cr in Mar'21 to 17.50 Cr in Mar'25. The company's earnings per share (EPS) have also shown growth, climbing from 6.84 in Mar'21 to 7.97 in Mar'25. On the balance sheet, total assets have expanded from 115.04 Cr in Mar'20 to 415.26 Cr in Mar'25, reflecting robust growth in shareholder's funds and reserves. Overall, Sakar Healthcare has demonstrated a solid financial performance with increasing revenues, profits, and asset growth over the years.

Who are the top shareholders of the Sakar Healthcare?

The top shareholders of Sakar Healthcare include Sanjay S Shah with 45.6%, Tata Capital Healthcare Fund II at 10.52%, and Foreign Institutional Investors holding 13.61%. Individual investors own 15.94%, with no pledged promoter holdings or mutual fund investments.

The top shareholders of Sakar Healthcare include the promoters, with Sanjay S Shah holding the largest share at 45.6%. Additionally, Tata Capital Healthcare Fund II is the highest public shareholder, owning 10.52%. Foreign Institutional Investors (FIIs) hold a combined 13.61% of the company through four different FIIs. Individual investors collectively own 15.94% of the shares. There are no pledged promoter holdings, and mutual funds do not currently hold any shares in the company.

When is the next results date for Sakar Healthcare?

No Upcoming Board Meetings

Has Sakar Healthcare declared dividend?

No Dividend History Available